Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Biogen Idec's Drug for Rare Disease Fails in Study


Shares are dropping after the big biotech company says it's scrapping an R&D program for Lou Gehrig's disease. But a new pill for multiple sclerosis continues to be the major catalyst for this stock.

MINYANVILLE ORIGINAL Biogen Idec's (NASDAQ:BIIB) experimental drug for a rare disease that destroys the brain and spinal cord nerve cells failed in a company study. Biogen says it is ending its research program for the drug, dexpramipexole.

The medicine was the in the late stages of testing for a treatment of amyotrophic lateral sclerosis, or ALS, which is also commonly known as Lou Gehrig's disease. While some Wall Street analysts viewed the drug as a long shot, study results were highly anticipated and the failure is a disappointing development for a company that has won over a number of investors since CEO George Scangos came aboard in June 2010. Scangos is seen as a leader who brought a more clear direction to the big biotech.

In morning trading, shares of Biogen dropped 4% to $144.65. (They fell 6% in pre-market trading.) The stock is still up 28% over the past 12 months.

"The sentiment hit is clearly real and important for a high-flying company that really has done no wrong in years," ISI Group analyst Mark Schoenebaum says.

But Schoenebaum and other Wall Street analysts are looking ahead for a much bigger catalyst in the stock, the upcoming Food and Drug Administration approval decision on BG12, a pill for multiple sclerosis that some analysts see as a potential blockbuster product. The FDA is expected to make a decision by March 28 (though a ruling can be made before that date). BG12 would compete with Novartis' (NYSE:NVS) Gilenya, the first oral treatment for MS. Biogen's drug is expected to take share from Gilenya, which was approved in 2010.

Schoenebaum previously estimated that Biogen's ALS drug would peak at around $400 million in annual sales by the end of the decade. By comparison, a consensus of analysts predicts BG12 annual sales will soar to more than twice that amount by 2014 (if the drug is approved this year).

Stifel Nicolaus analyst Joel Sendek said in a note Thursday that BG12 "has the potential to easily beat consensus estimates of $350 million and $908 million in 2013 and 2014."

Of course, the most unfortunate aspect of Biogen's ALS drug failure is that patients need a treatment. There is no cure for the disease and its cause is not understood. One of 10 ALS cases is due to a genetic defect, according to US health officials. Otherwise, the causes for the condition are unknown. ALS affects five out of every 100,000 people worldwide, according to government estimates. The disease, nicknamed after the famous New York Yankee Gehrig, is often fatal within a few years of diagnosis.

Biogen says it will continue to explore the genetic causes of the disease. Dexpramipexole was Biogen's only drug candidate for ALS.

Twitter: @brettchase

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos